Rezolute Shares Plunge After Phase 3 Trial Failure for Lead Drug Candidate
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Businesswire
- Clinical Trial Failure: Rezolute's shares plummeted on December 11, 2025, after its Phase 3 sunRIZE trial for ersodetug failed to meet both primary and key secondary endpoints, indicating significant challenges in developing its lead drug candidate for congenital hyperinsulinism.
- Severe Investor Reaction: The trial's inability to demonstrate statistically significant reductions in hypoglycemia events compared to placebo led to a sharp decline in stock price, reflecting market concerns over the company's future profitability and potentially impacting its financing and R&D capabilities.
- Legal Investigation Initiated: Faruqi & Faruqi LLP is investigating potential claims against Rezolute, suggesting that investors are questioning the management's transparency and accountability regarding the clinical trial results, which could lead to further legal risks.
- Market Confidence Eroded: This incident not only affects Rezolute's stock price but may also have long-term negative implications for its future drug development and market positioning, undermining investor confidence in its innovation capabilities.
RZLT
$1.77+Infinity%1D
Analyst Views on RZLT
Wall Street analysts forecast RZLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RZLT is 16.14 USD with a low forecast of 12.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.850
Low
12.00
Averages
16.14
High
20.00
Current: 1.850
Low
12.00
Averages
16.14
High
20.00
About RZLT
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
